SCHEMBL1463401

SCHEMBL1463401

Clc1ccc2nc(NC[C@@H]3CCNC3)cnc2c1

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 1/20 0.45
KDM1A O60341 1/20 0.43
MAOB P27338 2/20 0.41
HTR6 P50406 2/20 0.41
CCNT1 O60563 6/20 0.41
BRD4 O60885 1/20 0.40
ATAD2 Q6PL18 1/20 0.40
JAK2 O60674 1/20 0.39
JAK1 P23458 1/20 0.39
CDK9 P50750 1/20 0.39
TDO2 P48775 1/20 0.38
HCRTR1 O43613 1/20 0.38
HCRTR2 O43614 1/20 0.38
BACE1 P56817 1/20 0.38
PIM1 P11309 1/20 0.37
IRAK1 P51617 1/20 0.37
IRAK4 Q9NWZ3 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1465597 0.77 HCRTR1 (0.42) PIK3CAMAOBHTR6CCNT1HCRTR1
SCHEMBL1462935 0.75 S1PR3 (0.45) KDM1AMAOBHTR6BRD4ATAD2
SCHEMBL1463271 0.75 S1PR3 (0.45) KDM1AMAOBHTR6BRD4ATAD2
SCHEMBL7360534 0.70 CHEK1 (0.45) KDM1ACCNT1CDK9PIM1IRAK4
SCHEMBL18987118 0.69 USP30 (0.54) KDM1AMAOBHTR6BRD4ATAD2
SCHEMBL1463404 0.69 HRH4 (0.40) BACE1
SCHEMBL22075057 0.69 PIK3CA (0.38) PIK3CAKDM1AMAOBHTR6CCNT1
SCHEMBL1560169 0.68 SLC6A4 (0.38) IRAK4
SCHEMBL13326502 0.68 CDK4 (0.44) KDM1ABRD4ATAD2TDO2
SCHEMBL780564 0.68 PDGFRB (0.61)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8748430-B2 Pyrrolidin-3yl-methylamine quinoxaline derivatives Hoffmann-La Roche Inc (US) 2014-06-10 US disclosed
US-8748430-B2 Pyrrolidin-3yl-methylamine quinoxaline derivatives Hoffmann-La Roche Inc (US) 2014-06-10 US disclosed
US-8748430-B2 Pyrrolidin-3yl-methylamine quinoxaline derivatives Hoffmann-La Roche Inc (US) 2014-06-10 US disclosed
US-20120232084-A1 PYRROLIDIN-3-YLMETHYL-AMINE AS OREXIN ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2012-09-13 US disclosed
US-20120232084-A1 PYRROLIDIN-3-YLMETHYL-AMINE AS OREXIN ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2012-09-13 US disclosed
US-20120232084-A1 PYRROLIDIN-3-YLMETHYL-AMINE AS OREXIN ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2012-09-13 US disclosed
US-8207220-B2 Substituted benzothiazoles as orexin antagonists HOFFMANN-LA ROCHE INC. (US) 2012-06-26 US disclosed
US-8207220-B2 Substituted benzothiazoles as orexin antagonists HOFFMANN-LA ROCHE INC. (US) 2012-06-26 US disclosed
US-8207220-B2 Substituted benzothiazoles as orexin antagonists HOFFMANN-LA ROCHE INC. (US) 2012-06-26 US disclosed
EP-2303871-B1 PYRROLIDIN-3-YLMETHYL-AMINE AS OREXIN ANTAGONISTS HOFFMANN LA ROCHE (CH) 2012-05-09 EP disclosed
US-7923470-B2 Benzooxazoles as orexin antagonists HOFFMANN-LA ROCHE INC. (US) 2011-04-12 US disclosed
EP-2303871-A1 PYRROLIDIN-3-YLMETHYL-AMINE AS OREXIN ANTAGONISTS F. Hoffmann-La Roche AG (CH) 2011-04-06 EP disclosed
US-20110071154-A1 PYRROLIDIN-3-YLMETHYL-AMINE AS OREXIN ANTAGONISTS KNUST HENNER 2011-03-24 US disclosed
US-20110071154-A1 PYRROLIDIN-3-YLMETHYL-AMINE AS OREXIN ANTAGONISTS KNUST HENNER 2011-03-24 US disclosed
US-20110071154-A1 PYRROLIDIN-3-YLMETHYL-AMINE AS OREXIN ANTAGONISTS KNUST HENNER 2011-03-24 US disclosed
WO-2010012620-A1 PYRROLIDIN-3-YLMETHYL-AMINE AS OREXIN ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2010-02-04 WO disclosed
WO-2010012620-A1 PYRROLIDIN-3-YLMETHYL-AMINE AS OREXIN ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2010-02-04 WO disclosed
US-20100029664-A1 PYRROLIDIN-3-YLMETHYL-AMINE AS OREXIN ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2010-02-04 US disclosed
US-20100029664-A1 PYRROLIDIN-3-YLMETHYL-AMINE AS OREXIN ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2010-02-04 US disclosed
US-20100029664-A1 PYRROLIDIN-3-YLMETHYL-AMINE AS OREXIN ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2010-02-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110071154-A1 PYRROLIDIN-3-YLMETHYL-AMINE AS OREXIN ANTAGONISTS HCRTR2, HCRTR1, NPY2R PIK3CA 3831/4885KDM1A 1107/4885MAOB 594/4885
US-20100029664-A1 PYRROLIDIN-3-YLMETHYL-AMINE AS OREXIN ANTAGONISTS HCRTR2, HCRTR1, NPY2R PIK3CA 3831/4885KDM1A 1107/4885MAOB 594/4885
US-20120232084-A1 PYRROLIDIN-3-YLMETHYL-AMINE AS OREXIN ANTAGONISTS HCRTR2, HCRTR1, NPY2R PIK3CA 3831/4885KDM1A 1107/4885MAOB 594/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.